pneumoniae

Chlamydia pneumoniae-IN-1 (compound 55), a benzimidazole derivative, exhibits potent antibacterial activity, inhibiting 99% of C. pneumoniae growth at a concentration of 10 μM while maintaining 95% viability of host cells. It effectively inhibits the CV-6 strain of C. pneumoniae with a minimum inhibitory concentration (MIC) of 12.6 μM, demonstrating its antichlamydial efficacy [1].

Blasticidin S HCl is a peptide-based nucleoside antibiotic (antibiotic) isolated from Streptomyces griseochromogenes that inhibits prokaryotic and eukaryotic protein synthesis by interfering with the formation of peptide bonds in the ribosome.

LpxH-IN-AZ1 is a potent inhibitor of the UDP-2,3-diacylglucosamine pyrophosphate hydrolase, LpxH, and sulfonylpiperazine compounds.LpxH-IN-AZ1 exhibits antimicrobial activity and inhibits Klebsiella pneumoniae with an IC50 of 0.36 μM.

α-(difluoromethyl)-DL-Arginine (RMI 71897) is an enzyma-activated, irreversible inhibitor of arginine decarboxylase for E. coli (Ki = 800 μM), Pseudomonas aeruginosa, and Klebsiella pneumoniae. At 0.01 mM, it has been shown to prevent osmotic stress-induced increases in arginine decarboxylase activity and putrescine synthesis in oat leaf cells. When combined with a variety of polyamine analogues, α-(difluoromethyl)-DL-Arginine inhibited the growth of Trypanosoma Crui in mammalian host cells at a minimum concentration of 10 mM and prevented the growth of Trypanosoma Crui in T-cell receptor alpha-deficient mouse models.

PF-04753299 is a potent and selective inhibitor of UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC), demonstrating bactericidal effects against gonococcal isolates and exhibiting inhibitory activity against E. coli, P. aeruginosa, and K. pneumoniae, with minimum inhibitory concentration (MIC) 90 values of 2 μg ml, 4 μg ml, and 16 μg ml, respectively. This compound is utilized in researching gram-negative bacterial infections [1].

Meropenem (SM 7338) is a broad-spectrum carbapenem antibiotic administered intravenously for severe bacterial infections caused by sensitive agents. It commonly causes mild, transient aminotransferase elevations and can rarely lead to clinically apparent cholestatic liver injury.

Moxifloxacin (Avelox) is a fourth-generation fluoroquinolone that has been shown to be effective against Gram-positive, Gram-negative, and atypical strains, as well as multi-drug resistant Streptococcus pneumoniae.

3,5-Dimethylbenzaldehyde has broad-spectrum antimicrobial activity, inhibiting Bacillus subtilis, Pseudomonas albicans, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus and Streptococcus pneumoniae.

Delafloxacin (WQ-3034) (RX-3341, ABT-492) is a fluoroquinolone antibiotic agent. It has potent inhibitory against levofloxacin-resistant Streptococcus pneumoniae strains (MIC: 0.0078-0.125 μg ml).

Colistin (Polymyxin E), a polypeptide antibiotic with oral activity, exhibits strong efficacy against a range of Gram-negative rod-shaped bacteria, such as multidrug-resistant Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae. However, its use is associated with nephrotoxicity. It is primarily utilized in researching infections caused by Gram-negative bacilli [1] [2].

CHEMBL1276927 (N-(3-(1H-benzo[d]imidazol-2-yl)phenyl)-3-methylbenzamide) shows antibacterial and antiparasitic activities against Chlamydia pneumoniae and Leishmania donovani.

Faropenem daloxate (Faropenem medoxil) is useful for penem and antibiotics. Faropenem medoxomil has excellent in vitro activity against Streptococcus pneumoniae, Haemophilus influenzae and other key pathogens implicated in acute bacterial rhinosinusitis.Faropenem daloxate is the first oral penem in a new class of beta-lactam antibiotics.

JH-LPH-33 is a UDP-2,3-diacylglucosamine pyrophosphate hydrolase LpxH inhibitor with antimicrobial activity for the study of bacterial infections.

Cefditoren is an antibiotic characterized by its oral efficacy and broad-spectrum antimicrobial activities, effectively inhibiting both Gram-negative and Gram-positive bacterial activities. It displays a MIC50 of 0.25-0.5 mg L against Streptococcus pneumoniae strains. Additionally, Cefditoren is utilized in treating respiratory and skin infections.

Nafithromycin (WCK 4873) serves as an orally administered antibiotic effective against community-acquired pneumonia organisms such as Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Methicillin-susceptible Staphylococcus aureus. It displays a minimum inhibitory concentration (MIC 90) of 0.12 mg liter against both macrolide-resistant and telithromycin-insensitive Streptococcus pneumoniae.

RNAP-NusG-IN-1 is an inhibitor of RNAP-NusG. It exhibits antibacterial (bacterial) activity against Gram-positive bacteria, with the most potent effect observed in Streptococcus pneumoniae, where the minimum inhibitory concentration (MIC) is 1 μg mL.

MLEB-22043 is a synthetic siderophore-monocyclic β-lactam conjugate which enters bacteria through TonB-dependent transport proteins utilizing its siderophore component, subsequently exerting antibacterial activity via its β-lactam portion. This compound acts as a broad-spectrum antibiotic, exhibiting significant inhibitory activity against pathogens such as Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Pseudomonas aeruginosa.

Debio-1452-NH3 is a novel and potent FabI antibody—enoyl-acyl carrier protein reductase inhibitor that demonstrates excellent efficacy in reducing bacterial load in mice. It effectively treats lethal infections caused by clinically isolated strains of Pseudomonas aeruginosa (Acinetobacter baumannii), Klebsiella pneumoniae, and Escherichia coli (E. coli).

LB 11058 is a novel injectable cephalosporin featuring a C-3 pyridyl-substituted vinyl sulfide and a C-7 2-amino-5-chloro-1,3-thiazole group. This compound exhibits exceptional activity against Streptococcus pneumoniae and demonstrates similar efficacy against β-hemolytic streptococci. The inhibition pattern for LB 11058 with S. aureus is consistent, as all isolates are inhibited under this pattern.

YFJ-36 is an antibiotic that demonstrates superior and broad-spectrum antibacterial activity in vitro compared to cefiderocol, particularly against A. baumannii and K. pneumoniae. In a systemic infection model in mice, YFJ-36 exhibits strong in vivo efficacy. Additionally, the compound shows enhanced physicochemical stability in liquid media with a pH of 6-8 and is noteworthy for its potential to reduce allergy risk due to its quaternary ammonium bond.

DNA Gyrase-IN-15 (Compound 11) is an antibacterial agent that inhibits both DHPS and DNA gyrase, with IC50 values of 1.73 and 0.07 µM, respectively. It shows antimicrobial activity against Enterococcus faecium (MIC of 15.62 µg mL), Acinetobacter baumannii, Enterobacter (MIC of 7.81 µg mL), Pseudomonas aeruginosa, Klebsiella pneumoniae, and Staphylococcus aureus. Additionally, DNA Gyrase-IN-15 exhibits antibiofilm activity against Enterococcus faecium.

KPC-IN-1 (compound 1e) is an inhibitor of Klebsiella pneumoniae carbapenemase KPC-2, with an IC50 value of 8.3 nM. KPC is a β-lactamase expressed in Gram-negative bacteria that hydrolyzes carbapenems, leading to significant bacterial resistance to carbapenem antibiotics.

Solithromycin (OP-1068) is an orally bioavailable antimicrobial agent that inhibits cell viability, protein synthesis, and growth rate of Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus aureus, and Haemophilus influenzae with IC50 values of 7.5 ng mL, 40 ng mL, and 125 ng mL, respectively.Solithromycin inhibits protein biosynthesis by binding to the large 50S subunit of the ribosome.

Lysobactin, also known as katanosin B, is an effective antibiotic with in vivo efficacy against Staphylococcus aureus and Streptococcus pneumoniae. It was previously shown to inhibit peptidoglycan (PG) biosynthesis.